Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

The virtual clinical trial service providers market is projected to grow at an annualized rate{Roots}


Narender

3 views

Roots Analysis has done a detailed study on Virtual Clinical Trial Service Providers Market, 2020-2050, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 280+ page report, which features 180+ figures and 230+ tables, please visit this link

 

Key Market Insights

§  Currently, many companies claim to have advanced technology platforms, which enable them to decentralize the clinical research process, thereby, optimizing associated costs and the total time spent on conducting trials

§  The virtual clinical trials landscape is presently dominated by the presence of small-sized companies; majority of the players are headquartered in North America

§  Considering the cost and time-related benefits of using modern technology solutions in clinical research, several investors have opted to fund the initiatives of companies engaged in the development of such solutions

§  Case Study: Pharmaceutical players have already conducted a number of virtual clinical studies, mostly upon encountering constraints with the conventional approach and developing the means to overcome them

§  The annual number of virtual trials, across different therapeutic areas, is on the rise; leveraging telehealth platforms and remote monitoring systems, both small and established companies are using this format

§  The rising interest of stakeholders in decentralized clinical trials is evident in the growing partnership activity; companies inked deals based on a variety of collaboration models and applications, worldwide

§  Owing to the tremendous rise in cost and complexity of conventional clinical research, the market opportunity for virtual clinical trials is poised to grow at a CAGR of 14% till 2050

§  The projected opportunity within the virtual clinical trials market is expected to be well distributed within different phases of development and end users, across the globe

 

For more information, please visit https://www.rootsanalysis.com/reports/virtual-clinical-trial-service-provides-market.html

 

Table of Contents

 

1.                     PREFACE

1.1.                   Scope of the Report

1.2.                   Research Methodology

1.3.                   Key Questions Answered

1.4.                   Chapter Outlines

 

2.                     EXECUTIVE SUMMARY

 

3.                     INTRODUCTION

3.1.                   Chapter Overview

3.2.                   Existing Constraints in Clinical Research

3.2.1.               Increasing Complexity and Cost of Trials

3.2.2.                Evolving Regulatory Standards

3.2.3.                Patient Recruitment and Retention Challenges

3.2.4.                Data Handling-related Concerns

 

3.3.                   Virtual Clinical Trials                 

3.3.1.                Key Aspects of Virtual Clinical Trials

3.3.1.1.             Study Design

3.3.1.2.             Patient Recruitment and Retention

3.3.1.3.             Remote Monitoring

3.4.1.4.             Data Collection and Analysis

 

3.3.2.                Advantages and Disadvantages of Virtual Clinical Trials

 

3.4.                   Emerging Trends in Clinical Drug Development                          

3.4.1.                Innovative Trial Designs

3.4.2.                Real-world Evidence

3.4.3.                Patient Centricity

3.4.4.                Big Data Analytics

3.4.5.                Blockchain Technology

3.5.                   Future Perspectives

           

4.                     VIRTUAL CLINICAL TRIAL SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE

.1.                    Chapter Overview

4.2.                   Virtual Clinical Trial Service Providers: Overall Market Overview

4.2.1.                Analysis by Year of Establishment

4.2.2.                Analysis by Company Size

4.2.3.                Analysis by Geography

4.2.4.                Analysis by Type of Service Offered

 

5.                     COMPANY PROFILES

5.1.                   Chapter Overview

5.2.                   Cambridge Cognition

5.2.1.                Company Overview

5.2.2.                Technology Overview

5.2.3.                Recent Developments and Future Outlook

 

5.3.                   Center Point Clinical Services

5.3.1.                Company Overview

5.3.2.                Technology Overview

.3.3.                  Recent Developments and Future Outlook

 

5.4.                   eClinicalHealth

5.4.1.                Company Overview

5.4.2.                Technology Overview

5.4.3.                Recent Developments and Future Outlook

 

5.5.                   IQVIA

5.5.1.                Company Overview

5.5.2.                Technology Overview

5.5.3.                Recent Developments and Future Outlook

 

5.6.                   Mytrus (Medidata Solutions)

5.6.1.                Company Overview

5.6.2.                Technology Overview

5.6.3.                Recent Developments and Future Outlook

5.7.                   PanAmerican Clinical Research

5.7.1.                Company Overview

5.7.2.                Technology Overview

5.7.3.                Recent Developments and Future Outlook

 

5.8.                   Science 37

5.8.1.                Company Overview

5.8.2.                Technology Overview

5.8.3.                Recent Developments and Future Outlook

 

5.9.                   VirTrial

5.9.1.                Company Overview

5.9.2.                Technology Overview

5.9.3.                Recent Developments and Future Outlook

 

6.                     CASE STUDY: VIRTUAL CLINICAL TRIAL-RELATED INITIATIVES OF BIG PHARMA PLAYERS

6.1.                   Chapter Overview

6.2.                   Virtual Clinical Trial-Related Initiatives of Big Pharma Players

6.2.1.                Pfizer

6.2.1.1.             Initial Approach and Key Learnings

6.2.1.2.             Future Perspective

 

6.2.2.                Johnson & Johnson

6.2.2.1.             Initial Approach and Key Learnings

6.2.2.2.             Future Perspective

 

6.2.3.                Sanofi

6.2.3.1.             Initial Approach and Key Learnings

6.2.3.2.             Future Perspective

 

6.2.4.                Novartis

6.2.4.1.             Initial Approach and Key Learnings

6.2.4.2.             Future Perspective

 

6.2.5.                GlaxoSmithKline

6.2.5.1.             Initial Approach and Key Learnings

6.2.5.2.             Future Perspective

 

6.2.6.                Amgen

6.2.6.1.             Initial Approach and Key Learnings

6.2.6.2.             Future Perspective

 

6.2.7.                AstraZeneca

6.2.7.1.             Initial Approach and Key Learnings

6.2.7.2.             Future Perspective

 

7.                     CASE STUDY: TRADITIONAL VERSUS VIRTUAL CRO

7.1.                   Chapter Overview

7.2.                   Comparison between Traditional and Virtual CROs

7.3.                   Key Attributes of a Virtual CRO

7.4.                   The Virtual Operating Model

7.5.                   Concluding Remarks

 

8.                     FUNDING AND INVESTMENT ANALYSIS

8.1.                   Chapter Overview

8.2.                   Types of Funding

8.3.                   Virtual Clinical Trial Service Providers: Funding and Investment Analysis

8.3.1.                Analysis by Year of Investment

8.3.2.                Analysis by Amount Invested

8.3.3.                Analysis by Type of Funding

8.3.4.                Most Active Players

8.3.5.                Most Active Investors

8.4.                   Concluding Remarks

 

9.                     PARTNERSHIPS & COLLABORATIONS

9.1.                   Chapter Overview

9.2.                   Partnership Models

9.3.                   Virtual Clinical Trial Service Providers: Partnership and Collaborations

9.3.1.                Analysis by Year of Partnership

9.3.2.                Analysis by Type of Partnership

9.3.3.                Analysis by Focus Area Mentioned in Agreement

9.3.4.                Analysis by Target Therapeutic Area Mentioned in Agreement

9.3.5.                Analysis by Year of Partnership and Type of Partner

9.3.6.                Most Active Players: Analysis by Number of Partnerships

9.3.7.                Geographical Analysis

9.3.9.                Intercontinental and Intracontinental Agreements

 

10.                    COVID-19 IMPACT

10.1.                 Chapter Overview

10.2.                 Impact of COVID-19 on Clinical Trials

10.3.                 Impact on Future Opportunity for Virtual Clinical Trials Service Providers

 

11.                    CLINICAL TRIAL ANALYSIS

11.1.                 Chapter Overview

11.2.                 Scope and Methodology

11.3.                 Virtual Clinical Trials: Clinical Trial Analysis

11.3.1.              Analysis by Trial Registration Year

11.3.2.              Analysis by Trial Phase

11.3.3.              Analysis by Trial Status

11.3.4.              Analysis by Trial Design

11.3.5.              Analysis by Type of Sponsor

11.3.6.              Analysis by Target Therapeutic Area

11.3.7.             Geographical Analysis by Number of Registered Trials

11.3.8.             Geographical Analysis by Number of Patients Enrolled

 

12.                    MARKET OPPORTUNITY ASSESSMENT

12.1.                 Chapter Overview

12.2.                 Key Assumptions and Forecast Methodology

12.3.                 Virtual Clinical Trial Service Providers: Overall Market Opportunity, 2020-2050

12.3.1.              Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Therapeutic Area

12.3.2.              Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by End-user

12.3.3.              Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by Trial Phase

12.3.4.              Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by Geography

 

12.4.                 Virtual Clinical Trial Services Market in North America, 2020-2050

12.4.1.              Virtual Clinical Trial Services Market in North America: Distribution by Therapeutic Area, 2020-2050

12.4.1.1.           Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050

12.4.1.1.1.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies

12.4.1.1.2.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies

12.4.1.1.3.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies

12.4.1.1.4.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies

 

12.4.2.1.           Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050

12.4.2.1.1.        Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies

12.4.2.1.2.        Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies

12.4.2.1.3.        Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies

12.4.2.1.4.        Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies

 

12.4.3.1.           Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050

12.4.3.1.1.        Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies

12.4.3.1.2.        Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies

12.4.3.1.3.        Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies

12.4.3.1.4.        Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies

 

12.4.4.1.           Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050

12.4.4.1.1.        Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase I Studies

12.4.4.1.2.        Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase II Studies

12.4.4.1.3.        Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase III Studies

12.4.4.1.4.        Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase IV Studies 

 

12.4.5.1.           Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050

12.4.5.1.1.        Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies

12.4.5.1.2.        Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies

12.4.5.1.3.        Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies

12.4.5.1.4.        Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies

 

12.4.6.1.           Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050

12.4.6.1.1.        Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies

12.4.6.1.2.        Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies

12.4.6.1.3.        Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies

12.4.6.1.4.        Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies

12.4.7.1.          Virtual Clinical Trial Services Market for Other Therapeutic Areas in North America, 2020-2050

12.4.7.1.1.        Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase I Studies

12.4.7.1.2.        Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase II Studies

12.4.7.1.3.        Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase III Studies

12.4.7.1.4.        Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase IV Studies

 

12.5.                 Virtual Clinical Trial Services Market in Europe, 2020-2050

12.5.1.              Virtual Clinical Trial Services Market in Europe: Distribution by Therapeutic Area, 2020-2050

12.5.1.1.           Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050

12.5.1.1.1.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies

12.5.1.1.2.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies

12.5.1.1.3.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies

12.5.1.1.4.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies

 

12.5.2.1.           Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050

12.5.2.1.1.        Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies

12.5.2.1.2.        Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies

12.5.2.1.3.        Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies

12.5.2.1.4.        Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies

 

12.5.3.1.           Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050

12.5.3.1.1.        Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies

12.5.3.1.2.        Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies

12.5.3.1.3.        Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies

12.5.3.1.4.        Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies

             

12.5.4.1.           Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050

12.5.4.1.1.        Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase I Studies

12.5.4.1.2.        Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase II Studies

12.5.4.1.3.        Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase III Studies

12.5.4.1.4.        Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase IV Studies

 

12.5.5.1.           Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050

12.5.5.1.1.        Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies

12.5.5.1.2.        Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies

12.5.5.1.3.        Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies

12.5.5.1.4.        Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies

 

12.5.6.1.           Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050

12.5.6.1.1.        Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies

12.5.6.1.2.        Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies

12.5.6.1.3.        Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies

12.5.6.1.4.        Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies

 

12.5.7.1.           Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050

12.5.7.1.1.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase I Studies

12.5.7.1.2.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase II Studies

12.5.7.1.3.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase III Studies

12.5.7.1.4.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase IV Studies

 

12.6.                 Virtual Clinical Trial Services Market in Asia-Pacific, 2020-2050

12.6.1.              Virtual Clinical Trial Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2020-2050

12.6.1.1.           Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050

12.6.1.1.1.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies

12.6.1.1.2.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies

12.6.1.1.3.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies

12.6.1.1.4.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

 

12.6.2.1.           Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050

12.6.2.1.1.        Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies

12.6.2.1.2.        Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies

12.6.2.1.3.        Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies

12.6.2.1.4.        Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

             

12.6.3.1.           Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050

12.6.3.1.1.         Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies

12.6.3.1.2.        Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies

12.6.3.1.3.        Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies

12.6.3.1.4.        Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

 

12.6.4.1.           Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050

12.6.4.1.1.        Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies

12.6.4.1.2.        Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies

12.6.4.1.3.        Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies

12.6.4.1.4.        Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

 

12.6.5.1.           Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050

12.6.5.1.1.        Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies

12.6.5.1.2.        Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies

12.6.5.1.3.        Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies

12.6.5.1.4.        Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

 

12.6.6.1.           Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050

12.6.6.1.1.        Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies

12.6.6.1.2.        Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies

12.6.6.1.3.        Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies

12.6.6.1.4.        Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

12.6.7.1.           Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050

12.6.7.1.1.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase I Studies

12.6.7.1.2.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase II Studies

12.6.7.1.3.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase III Studies

12.6.7.1.4.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase IV Studies

 

12.7.                 Virtual Clinical Trial Services Market in Rest of the World, 2020-2050

12.7.1.              Virtual Clinical Trial Services Market in Rest of the World: Distribution by Therapeutic Area, 2020-2050

12.7.1.1.           Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050

12.7.1.1.1.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies

12.7.1.1.2.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies

12.7.1.1.3.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies

12.7.1.1.4.        Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

 

12.7.2.1.           Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050

12.7.2.1.1.        Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies

12.7.2.1.2.        Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies

12.7.2.1.3.        Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies

12.7.2.1.4.        Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

 

12.7.3.1.           Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050

12.7.3.1.1.        Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies

12.7.3.1.2.        Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies

12.7.3.1.3.        Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies

12.7.3.1.4.        Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

 

12.7.4.1.           Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050

12.7.4.1.1.        Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies

12.7.4.1.2.        Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies

12.7.4.1.3.        Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies

12.7.4.1.4.        Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

 

12.7.5.1.           Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050

12.7.5.1.1.        Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies

12.7.5.1.2.        Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies

12.7.5.1.3.        Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies

12.7.5.1.4.        Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

 

12.7.6.1.           Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050

12.7.6.1.1.        Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies

12.7.6.1.2.        Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies

12.7.6.1.3.        Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies

12.7.6.1.4.        Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

 

12.7.7.1.           Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050

12.7.7.1.1.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase I Studies

12.7.7.1.2.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase II Studies

12.7.7.1.3.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase III Studies

12.7.7.1.4.        Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase IV Studies

 

13.                    CONCLUSION

 

14.                    INTERVIEW TRANSCRIPTS

14.1.                 Chapter Overview

14.2.                 ConsilX

14.2.1.              Interview Transcript: Himanshu Verma, Founder and Chief Executive Officer, ConsilX & Rajesh Jain, Co-Founder, ConsilX

 

14.3.                 EmpiraMed

14.3.1.              Interview Transcript: Greg Erman, President and Chief Executive Officer, EmpiraMed

 

14.4.                 Andaman7

14.4.1.             Interview Transcript: Phillipe Lemmens, Chief Operating Officer, Andaman7

 

14.5.                 uMotif

14.5.1.             Interview Transcript: Jonathan Moshinsky, Head of Market Strategy, uMotif

 

15.                    APPENDIX 1: TABULATED DATA

 

16.                    APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...